Results 191 to 200 of about 686,182 (220)

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Cancer Research, 2008
Abstract Selective kinase inhibitors have had a substantial impact on the field of medical oncology. Whereas these agents can elicit dramatic clinical responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.
Ultan, McDermott, A John, Iafrate, Nathanael S, Gray, Toshi, Shioda, Marie, Classon, Shyamala, Maheswaran, Wenjun, Zhou, Hwan Geun, Choi, Shannon L, Smith, Lori, Dowell, Lindsey E, Ulkus, Georgiana, Kuhlmann, Patricia, Greninger, James G, Christensen, Daniel A, Haber, Jeffrey, Settleman   +15 more
openaire   +2 more sources

Molecular Biology of Anaplastic Lymphoma Kinase–Positive Anaplastic Large-Cell Lymphoma

Journal of Clinical Oncology, 2002
ABSTRACT: Anaplastic large-cell lymphoma (ALCL) provides an excellent example of how molecular insights into tumor pathogenesis are influencing and improving tumor classification. ALCL was described initially as a subtype of T-cell/null-cell lymphoma characterized by unusual tumor cell morphology and the expression of CD30.
Jeffery L, Kutok, Jon C, Aster
openaire   +2 more sources

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

Nature Medicine, 2008
An ideal vaccination strategy against tumors relies on specific antigens that are required for tumor maintenance. For lymphoma, vaccination with subject-specific immunoglobulin idiotypes has had the most promising results. Here we show that DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK ...
CHIARLE, Roberto, MARTINENGO, CINZIA, MASTINI, CRISTINA, AMBROGIO, CHIARA, D’Escamard V, FORNI, Guido, INGHIRAMI, Giorgio   +6 more
openaire   +3 more sources

Anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma

Egyptian Journal of Dermatology and Venereology
Anaplastic large-cell lymphoma (ALCL) is a non-Hodgkin T-cell lymphoma characterized by persistent expression of CD 30 antigen that represents 2–3% of non-Hodgkin lymphoma (NHL). ALCL may present as a primary cutaneous disease or systemic disease with secondary cutaneous involvement. World Health Organization (WHO) classifies ALCL into ALK-positive and
Shraddha Kote, Samruddhi Chopkar, Bhagyashree Supekar, Jayesh Mukhi   +3 more
openaire   +1 more source

Anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma presenting as a bladder neoplasm

Pathology International, 2008
Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration. Most of the examples in the literature have been reported as single cases. Reported herein is the case of a 45‐year‐old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK)
José Javier, Gómez-Román, María Luisa Cagigal, Cobo, José Fernando, Val-Bernal   +2 more
openaire   +2 more sources

Anaplastic lymphoma kinase inhibitors

Reactions Weekly, 2019
  +5 more sources

Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)

Leukemia and Lymphoma, 2021
Mei-Ting Chen, Zhao Wang
exaly  

Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)

Expert Opinion on Therapeutic Patents, 2020
Yi-Min Liu, Jing-Ping Liou, Chun-Nan Kuo
exaly  

Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma

Blood, 1999
Randy D Gascoyne, Stephan W Morris, Patricia Aoun   +2 more
exaly  

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review

Expert Opinion on Therapeutic Patents, 2014
Eugen F Mesáros, Gregory R Ott, Bruce D Dorsey   +2 more
exaly